A Double-Blind, Randomized, Placebo-Controlled, Single Ascending Dose Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers
Latest Information Update: 07 Mar 2023
At a glance
- Drugs Quemliclustat (Primary)
- Indications Cancer; Colorectal cancer; Pancreatic cancer; Prostate cancer
- Focus Pharmacokinetics
- Sponsors Arcus Biosciences
- 14 Dec 2021 Status changed from recruiting to completed.
- 14 Sep 2021 Planned End Date changed from 1 Aug 2021 to 1 Nov 2021.
- 14 Sep 2021 Planned primary completion date changed from 1 Aug 2021 to 1 Nov 2021.